Enanta is a biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases. Twitter guidelines: http://bit.ly/3v1nDMc
Location: United States, Massachusetts, Watertown
Investors 2
| Date | Name | Website |
| - | Industry V... | industryve... |
| - | Omega Fund... | omegafunds... |
Mentions in press and media 7
| Date | Title | Description |
| 23.06.2025 | XtalPi Announces Strategic Collaboration with Harvard Professor Gregory Verdine's DoveTree LLC to Advance Novel Therapeutics Using AI+Robotics Drug Discovery Platform | CAMBRIDGE, Mass. , June 23, 2025 /PRNewswire/ -- XtalPi, a global leader in AI- and robotics-powered drug and materials discovery, today announced it has signed a Letter of Intent (LOI) with DoveTree LLC, founded by Harvard University Profe... |
| 06.01.2017 | Genentech vet Troy Cox named Foundation Med CEO; Momenta inks a $600M collaboration deal | • Troy Cox, the senior VP of oncology sales and marketing at Genentech, is leaving the big Roche subsidiary to take the CEO’s job at Foundation Medicine $FMI. Longtime CEO Michael Pellini is taking the chairman’s post as Al... |
| 10.02.2015 | Looks like BioVentures is in the midst of raising a new $100M fund | The venture firm typically invests $3 million to $10 million, it says, and does operate like your typical VC, however: “Generally, we like to see a business plan that calls for total capital requirement of $15 million to $20 million to reac... |
| 19.04.2012 | ABBOTT PRESENTS POSITIVE RESULTS FROM INTERFERON-FREE PHASE 2 "CO-PILOT" STUDY FOR THE TREATMENT OF HEPATITIS C | – Results among the Most Mature Data for an Interferon-Free Regimen, Including 36-Week Post-Treatment Sustained Viral Response for a 12-Week Treatment Regimen – ABBOTT PARK, Ill., and Watertown, Mass., Apr. 19, 2012 – Abbott and Enanta Pha... |
| 19.04.2012 | APRIL 19, 2012 ABBOTT PRESENTS POSITIVE RESULTS FROM INTERFERON-FREE PHASE 2 "CO-PILOT" STUDY FOR THE TREATMENT OF HEPATITIS C | – More than 90 Percent of Patients New to HCV Treatment Achieved Sustained Viral Response through 12 Weeks – ABBOTT PARK, Ill., and Watertown, Mass., Apr. 19, 2012 – Abbott and Enanta Pharmaceuticals announced data from “Co-Pilot,” an inte... |
| 04.04.2012 | ENANTA ANNOUNCES POSITIVE PHASE 2 RESULTS FROM INTERFERON-FREE COMBINATION STUDIES WITH ABT-450 FOR HEPATITIS C TREATMENT TO BE PRESENTED AT EASL | – Poster Presentations to Include Enanta’s Nucleotide HCV Polymerase Inhibitor Program and Additional ABT-450 Data – WATERTOWN, Mass., April. 4, 2012 — Enanta Pharmaceuticals, Inc., a research and development company dedicated to creating ... |
| - | Looks like BioVentures is in the midst of raising a new $100M fund | Hey, life science startups: Looks like Massachusetts investment firm BioVentures is raising a new venture fund – and has raised about $20 million of a potential $100 million pot, according to a regulatory filing. Historically, the fund’s be... |